Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose-escalation Trial of CD33xCD3 Bispecific Antibody in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT05077423 is registered in ClinicalTrials.gov with Y-mAbs Therapeutics as lead sponsor.

NCT NCT05077423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose-escalation Trial of CD33xCD3 Bispecific Antibody in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Y-mAbs Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
May 25, 2022
Completion date
December 1, 2022
Enrollment
3 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

aml, childhood